MANNKIND CORP Impairment of Long-Lived Assets Held-for-use
MANNKIND CORP (MNKD) reported Impairment of Long-Lived Assets Held-for-use of $203.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2019-02-26
- MANNKIND CORP impairment of long-lived assets held-for-use for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- MANNKIND CORP impairment of long-lived assets held-for-use for the quarter ending 2017-09-30 was $92.00K.
- MANNKIND CORP impairment of long-lived assets held-for-use for the quarter ending 2017-06-30 was $111.00K.
- MANNKIND CORP impairment of long-lived assets held-for-use for the quarter ending 2016-12-31 was $564.00K.
- MANNKIND CORP impairment of long-lived assets held-for-use for fiscal 2017 was $203.00K, a 83.88% decline from fiscal 2016.
- MANNKIND CORP impairment of long-lived assets held-for-use for fiscal 2016 was $1.26M, a 99.10% decline from fiscal 2015.
- MANNKIND CORP impairment of long-lived assets held-for-use for fiscal 2015 was $140.41M.
- MANNKIND CORP impairment of long-lived assets held-for-use for fiscal 2014 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 9 month as first filed | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $92.00K derived: sum of 2 quarters · filed 2019-02-26 | $203.00K derived: sum of 3 quarters · filed 2019-02-26 | $203.00K 10-K · filed 2019-02-26 | |
| 2017-09-30 | $92.00K 10-Q · filed 2018-11-01 | $203.00K derived: sum of 2 quarters · filed 2018-11-01 | $203.00K 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | $111.00K 10-Q · filed 2018-08-02 | $111.00K 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | $564.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $1.26M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $695.00K 10-Q · filed 2017-11-07 | $700.00K 10-Q · filed 2016-11-09 | |||
| 2015-12-31 | $140.41M 10-K · filed 2018-02-27 | ||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 | ||||
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |